Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

December 06, 2023 00:21:48
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
COR2ED - Oncology Medical Conversation
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics

Dec 06 2023 | 00:21:48

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

Other Episodes

Episode

November 25, 2024 00:23:25
Episode Cover

Testing to treatment of BRAF-mutant metastatic NSCLC

 Testing to treatment of BRAF-mutant metastatic NSCLC    In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of...

Listen

Episode

April 28, 2025 00:18:36
Episode Cover

The HER2 diagnostic and treatment landscape in NSCLC

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC  This is the second episode of a two-part series on the HER2 diagnostic and treatment...

Listen

Episode

December 06, 2023 00:27:27
Episode Cover

Gastric and GEJ cancers: Clinical case discussions. Part 1 - non-metastatic disease

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals...

Listen